Page 20 - 2022_01-Haematologica-web
P. 20
G. Cartron and J. Trotman
B
A Figure 1. Results of immunochemothera- py with or without rituximab mainte- nance as first-line treatment in patients with follicular lymphoma. (A-C) Kaplan- Meier estimates of progression-free sur- vival (A); time to next anti-lymphoma treatment (B) and overall survival (C) from randomization. OS: overall survival; PFS: progression-free survival; TTNLT: time to next anti-lymphoma treatment; HR: haz- ard ratio; 95% CI: 95% confidence inter-
C
val. Adapted from Bachy E, et al.2.
12
haematologica | 2022; 107(1)
